Cytena

Executive Summary

Cytena, a German biotechnology company founded in 2014, specializes in single-cell dispensing and analysis systems for applications in cell line development, bioprocessing, and cell therapy. Its proprietary technology enables precise isolation and manipulation of individual cells, addressing critical needs in research and industrial bioproduction. By integrating microfluidics and automated imaging, Cytena's platforms improve efficiency and reproducibility in workflows such as clone picking, single-cell genomics, and cell therapy manufacturing. The company operates at the intersection of medical devices and life sciences tools, serving a growing market driven by advances in personalized medicine and biopharmaceuticals. With a focus on quality and throughput, Cytena has established a niche among academic labs, CROs, and biopharma companies. Its product portfolio includes the Cytena Single-Cell Printer and associated consumables, which are recognized for their gentle cell handling and high viability rates. As the cell therapy and gene editing sectors expand, Cytena is well-positioned to benefit from increased demand for reliable single-cell workflows. The company's strategic partnerships and ongoing R&D efforts underscore its commitment to innovation and market leadership.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation Single-Cell Printer with Enhanced Throughput75% success
• Q3 2026Strategic Collaboration with a Major Cell Therapy Developer60% success
• Q2 2027FDA Clearance for Clinical-Grade Single-Cell Dispensing System50% success